XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia. [PDF]
Shen L +20 more
europepmc +1 more source
Correction: Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib. [PDF]
Sałek-Zań A +7 more
europepmc +1 more source
A case of recurrent acute acalculous cholecystitis in a patient with renal cell carcinoma treated with pazopanib and axitinib: case report and literature review. [PDF]
Zeng X, Zhang J, Chen C, Sun X, Yang L.
europepmc +1 more source
Tyrosine kinase inhibitors in metastatic pheochromocytomas and paragangliomas: an updated systematic review and meta-analysis. [PDF]
Xu X +11 more
europepmc +1 more source
Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review). [PDF]
Cui H +10 more
europepmc +1 more source
Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. [PDF]
Bergerot C +9 more
europepmc +1 more source
CCR5, CD163, CSF1R, and FCGR3A as Candidate Biomarkers Associated With Mitophagy in Atherosclerosis. [PDF]
Fu J, Dong Y.
europepmc +1 more source
YAP delactylation enhances therapy resistance in renal cell carcinoma. [PDF]
Lin M +20 more
europepmc +1 more source
Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13-CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma. [PDF]
Uccello M.
europepmc +1 more source

